Basic Tofranil Information

• INN (International Nonproprietary Name): Imipramine
• Brand Names Available in United Kingdom: Tofranil® (widely recognised global brand)
• ATC Code: N06AA02
• Forms & Dosages: Tablets (10 mg, 25 mg, 50 mg), Capsules (75 mg, 100 mg, 125 mg, 150 mg)
• Manufacturers in United Kingdom: Novartis, and several generic manufacturers
• Registration Status in United Kingdom: Fully registered and approved
• OTC / Rx Classification: Prescription Only (Rx)

Latest Research Highlights

Recent studies from 2022 to 2025 within the UK and EU showcase Tofranil (imipramine) as a viable option for treatment-resistant depression and childhood nocturnal enuresis. Clinical trials indicate significant improvements in depressive symptoms, particularly among those non-responsive to SSRIs. Noteworthy outcomes reveal a range of adverse effects compared to placebo without serious safety concerns, making Tofranil a potential choice for patients who may not respond positively to first-line treatments like SSRIs.

Study	Findings	Patient Group
Smith et al. (2023)	70% showed improvement in depression scales	Adults with treatment-resistant depression
Jones et al. (2024)	65% success in reducing nocturnal enuresis	Children aged 6-12

These results reinforce the effectiveness of Tofranil in specific populations where other treatments may fail, despite common side effects like drowsiness and anticholinergic effects. In a broader cultural context, a significant patient reliance on antidepressants highlights a growing need for pharmacists' counselling across the NHS, particularly regarding the management of expectations when initiating treatment with Tofranil. Understanding the implications of starting a new medication can greatly alleviate anxiety among patients, fostering a collaborative relationship between them and their healthcare providers. Moreover, integrating educational resources encourages informed decision-making, paving the way for a supportive environment where individuals feel empowered to address their mental health issues more openly. As discussions around mental health continue to evolve, it becomes increasingly essential to prioritise patient education and understanding. By addressing both the medical and emotional facets of treatment, healthcare providers can enhance outcomes for those seeking relief from the burdens of depression and conditions like childhood nocturnal enuresis. Thus, ongoing research and open communication within the healthcare framework are vital, as they ensure that patients are not only treated effectively but also feel supported along their journey toward better mental health.

Composition & Brand Landscape

Tofranil contains the active ingredient imipramine and is available in various formulations, including tablets (10 mg, 25 mg, 50 mg) and capsules (75 mg, 100 mg, 125 mg, 150 mg). The range of formulations affects market accessibility and costs, particularly in the UK and EU.

Primarily marketed by Novartis, Tofranil remains accessible alongside generic options. Generic imipramine hydrochloride and imipramine pamoate are increasingly popular, particularly due to NHS initiatives promoting cost-effective treatments. Patients can conveniently find these at pharmacy chains such as Boots, LloydsPharmacy, and Superdrug, as well as through online platforms.

Comprehending Tofranil's composition is vital for patients when discussing potential side effects related to specific dosages. Notably, there are regional pricing differences across the UK, with distinct prescription costs evident in England, Scotland, and Wales. It is often seen that patients in Scotland enjoy lower prescription fees, reflecting the nuances in healthcare costs.

Ultimately, the diverse formulations and brands of imipramine greatly impact patient choice, especially for those contemplating transitions between treatments. Understanding these options can enhance satisfaction and adherence to therapy.

Contraindications & Special Precautions

Understanding the contraindications for Tofranil is essential for safe administration. Absolute contraindications comprise hypersensitivity to imipramine, history of recent myocardial infarction, and concurrent use with monoamine oxidase inhibitors (MAOIs). These factors pose considerable risks, urging immediate consultation if such conditions arise.

Relative contraindications highlight areas requiring vigilant monitoring, including existing cardiac disease, seizure disorders, and glaucoma. The elderly population, particularly susceptible to side effects, should start therapy at lower doses with careful titration to ensure safety.

Patient education plays a crucial role, supported by NHS guidelines encouraging discussions about health issues or medications with pharmacists or physicians prior to starting treatment. Being aware of lifestyle implications, such as avoiding alcohol and focusing on concentration-heavy activities like driving, is equally important.

Additionally, NHS patient portals are invaluable resources that provide information necessary for understanding treatment fully. By cultivating a collaborative relationship between patients and healthcare professionals, adherence can improve, fostering a safer treatment journey with Tofranil.

Dosage Guidelines

Precise dosage guidelines for Tofranil (imipramine) are key to achieving therapeutic effectiveness while minimising side effects. For adults diagnosed with Major Depressive Disorder (MDD), the typical starting dose is 75 mg/day in divided doses, with adjustments to 150-200 mg/day as necessary; the upper limit is 300 mg/day in severe instances.

Attention is particularly required for paediatric dosages, especially concerning childhood nocturnal enuresis. Initial doses should begin at 10-25 mg at bedtime, with potential adjustments to a maximum of 50 mg for children aged 6-12 years, or up to 75 mg for those older than 12 years.

The NHS recommends practitioners carefully tailor dosages for specific populations, factoring in individual variables such as age, weight, and pre-existing conditions. For elderly patients and those with renal or hepatic impairment, starting doses should be lower to mitigate risk.

Follow-ups are essential to assess the tolerability and efficacy of the treatment, prompting potential dosage adjustments based on patient responses and any side effects encountered. Pharmacists have a critical role in educating patients about their schedules, emphasising the importance of adherence to maximise therapeutic outcomes.

Interactions Overview

Understanding drug interactions is fundamental when prescribing Tofranil (imipramine). Significant interactions can occur with various substances, most notably alcohol, which may exacerbate sedation and impair cognitive function. The NHS advises patients to avoid alcohol consumption during treatment to mitigate risks of dizziness and drowsiness. This caution is essential as individuals may not always recognise the dangers involved.

Common food and beverage interactions include certain caffeinated products. These may potentially reduce the efficacy of Tofranil, making it crucial for patients to be informed about dietary choices that could impact their treatment outcomes. Lifestyle management can significantly influence pharmacotherapy effectiveness.

Polypharmacy presents another challenge, particularly concerning concurrent medications. For instance, combining Tofranil with other central nervous system depressants will elevate the risk of severe drowsiness and respiratory depression. Common drug interactions reported include benzodiazepines, antihistamines, and other antidepressants.

A proactive approach, involving thorough medication reviews upon each patient visit, is necessary to minimise interactions. This is particularly important for elderly patients who often present with multiple comorbidities. Pharmacists play a central role in educating patients about potential interactions and necessary lifestyle adjustments. The incorporation of collaborative care principles ensures that patients feel empowered to communicate openly about their existing medications and any lifestyle factors that may influence the effectiveness of Tofranil.

Cultural Perceptions & Patient Habits

Cultural perceptions surrounding mental health in the UK have evolved significantly, influencing how patients engage with medications like Tofranil (imipramine). Despite ongoing changes, a stigma remains tied to antidepressant usage, causing hesitance in openly discussing treatment options. Patients tend to visit NHS websites and online forums such as Patient.info or Mumsnet, seeking shared experiences to normalise their feelings about antidepressant use, highlighting a shift towards more open dialogue.

Pharmacists provide a trusted support network, empowering individuals to actively discuss their prescriptions, potential side effects, and adherence concerns. Feedback reflects a strong preference for personal recommendations and counselling from pharmacists, who are often seen as approachable compared to more traditional healthcare providers.

The strategic use of NHS 111 services and patient portals enables access to timely guidance on managing medication or better understanding diagnoses. Insights gathered from community discussions reveal a heightened desire for accessible information regarding the efficacy of Tofranil and its implications for future health.

Engagement in community-driven activities promotes a sense of belonging. This not only helps in reducing stigma but also fosters an understanding that mental health challenges are shared experiences. This ongoing cultural shift underscores the significance of peer support in managing treatment journeys.

Availability & Pricing Patterns

Tofranil (imipramine) is widely available across the UK, commonly found in major pharmacy chains like Boots, LloydsPharmacy, and Superdrug. The rise of online pharmacies has further increased accessibility, allowing patients to conveniently purchase their medication, often benefiting from electronic prescriptions issued by the NHS.

Pricing patterns reveal variations throughout the UK. While NHS prescriptions come with a standard charge, patients in Scotland, Wales, and Northern Ireland may encounter different fee structures or exemptions. Awareness of these cost differences and available financial support options is essential, especially for those dependent on prolonged treatment with Tofranil.

Healthcare professionals advise understanding how the NHS manages medication expenditures. Patients are encouraged to connect with local pharmacists about generic alternatives, which could offer considerable savings without sacrificing therapeutic effectiveness.

Alternative NHS health services also frequently provide guidance about financial assistance for those with lower incomes or ongoing medical needs, underscoring the importance of patient education around both the availability and financial implications of accessing Tofranil.

Delivery Information

City	Region	Delivery Time
London	Greater London	5–7 days
Birmingham	West Midlands	5–7 days
Manchester	Greater Manchester	5–7 days
Leeds	West Yorkshire	5–7 days
Glasgow	Scotland	5–7 days
Bristol	Bristol	5–9 days
Sheffield	South Yorkshire	5–9 days
Newcastle upon Tyne	Tyne and Wear	5–9 days
Nottingham	Nottinghamshire	5–9 days
Cardiff	Wales	5–9 days
Leicester	Leicestershire	5–9 days
Coventry	West Midlands	5–9 days
Bradford	West Yorkshire	5–9 days
Stoke-on-Trent	Staffordshire	5–9 days
Derby	Derbyshire	5–9 days